LLY vs NTLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Intellia Therapeutics exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position with a current ratio of 5.08 and low debt, it is plagued by massive operating losses (-428.86% margin) and a prohibitively high Price/Sales ratio of 26.08. Despite strong YoY revenue growth and positive analyst price targets, the combination of bearish insider selling and a long-term 5-year price decline of 78.8% suggests a high-risk speculative profile rather than a value investment.
Compare Another Pair
Related Comparisons
LLY vs NTLA: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Intellia Therapeutics, Inc. (NTLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.